Rapid Therapeutic Effects Seen With a JAK Inhibitor

EP: 1.Discussing the Pathophysiology of Alopecia Areata

EP: 2.Epidemiology Associated With Alopecia Areata

EP: 3.Common Comorbidities Associated With Alopecia Areata

EP: 4.Hallmark Symptoms Seen With Alopecia Areata

EP: 5.Psychosocial Impact of Alopecia Areata

EP: 6.Diagnosis of Alopecia Areata

EP: 7.Multimodal Care for Patients With Alopecia Areata

EP: 8.Deciding When to Treat Patients With Alopecia Areata

EP: 9.Choosing an Initial Therapy for Alopecia Areata

EP: 10.Adherence to Alopecia Areata Therapies

EP: 11.Adverse Events Associated With Conventional Alopecia Areata Therapies

EP: 12.Exploring Guidelines for Alopecia Areata

EP: 13.Unmet Needs for the Management of Alopecia Areata

EP: 14.Discussing Baricitinib for Alopecia Areata

EP: 15.Highlighting Deuruxolitinib for Alopecia Areata

EP: 16.Exploring Ritlecitinib for Alopecia Areata

EP: 17.Analyzing the Safety Data of JAK Inhibitors

EP: 18.SALT Scoring for Alopecia Areata

Now Viewing

EP: 19.Rapid Therapeutic Effects Seen With a JAK Inhibitor

Video content above is prompted by the following:

1. Ungar: The Severity of Alopecia Tool (SALT) is a validated tool utilized to assess the clinical severity of alopecia with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). In the Bayesian network meta-analysis, which JAK inhibitor(s) demonstrated the best relative effect in reducing SALT scores pre and post intervention?
   1. Which JAK inhibitor(s) demonstrated patients achieving 50% improvement?
   2. Which JAK inhibitor(s) demonstrated patients achieving 75% improvement?
   3. Do you believe this is an effective way to evaluate the effectiveness of an AA intervention?